Institutional & Family Asset Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.0% during the second quarter, Holdings Channel reports. The firm owned 14,164 shares of the biopharmaceutical company’s stock after selling 144 shares during the period. Institutional & Family Asset Management LLC’s holdings in Pfizer were worth $499,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Emerald Acquisition Ltd. purchased a new stake in shares of Pfizer during the second quarter worth approximately $555,074,000. Franklin Resources Inc. raised its position in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new position in Pfizer during the first quarter worth approximately $242,144,000. Jana Partners LLC raised its position in Pfizer by 46.8% in the first quarter. Jana Partners LLC now owns 13,460,304 shares of the biopharmaceutical company’s stock worth $398,963,000 after buying an additional 4,291,486 shares in the last quarter. Finally, Sound Shore Management Inc. CT bought a new position in Pfizer during the first quarter worth approximately $126,948,000. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 1.69% during mid-day trading on Friday, hitting $31.93. The company had a trading volume of 28,508,651 shares. The firm’s 50 day moving average is $33.36 and its 200 day moving average is $34.35. The company has a market capitalization of $193.68 billion, a price-to-earnings ratio of 28.31 and a beta of 0.86. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter last year, the company earned $0.56 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.76%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
A number of equities analysts recently commented on the company. Sanford C. Bernstein set a $36.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 19th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Pfizer in a research note on Tuesday, October 18th. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 price objective on the stock in a research note on Monday, October 17th. Jefferies Group lowered Pfizer from a “buy” rating to a “hold” rating and cut their price objective for the stock from $39.00 to $36.00 in a research note on Thursday, October 13th. Finally, Argus reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research note on Tuesday, October 4th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $38.48.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.